NEW YORK, Jan. 30 - Hybrigen and Bionomics have expanded their drug target-discovery relationship to include a new angiogenesis target discovered by Bionomics, the companies said on Wednesday.
They also announced plans jointly to launch a new enterprise to commercialize discoveries made in the collaboration.
The two companies inked a target discovery partnership last September to study two genes linked to breast cancer. Bionomics had identified and patented the genetic data, and Hybrigen brought its proteomic expertise to discover relevant drug targets. The two companies share rights to any drug targets developed in that collaboration.
The relationship will now include Bionomics' angiogenesis genes to which it has rights. Again, both companies will co-own the drug targets.
Bionomics, based in Adelaide, Australia, focuses on discovering and characterizing disease-related genes, especially in breast cancer, epilepsy, and angiogenesis.
Hybrigen is headquartered in Dallas, Tex. It has developed a proteomic platform to assist in drug target-discovery and characterization.